Similar articles for PMID: 36418168

Year	Number of Results
2005	1
2008	1
2009	2
2010	3
2011	1
2012	5
2013	6
2014	9
2015	11
2016	8
2017	9
2018	12
2019	10
2020	16
2021	7
2022	7
2023	12
2024	0

1

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study.

Lumish MA, Maron SB, Paroder V, Chou JF, Capanu M, Philemond S, O'Donoghue JA, Schöder H, Lewis JS, Lyashchenko SK, Pandit-Taskar N, Janjigian YY. Lumish MA, et al. J Nucl Med. 2023 May;64(5):724-730. doi: 10.2967/jnumed.122.264470. Epub 2022 Nov 23. J Nucl Med. 2023. PMID: 36418168 Free PMC article.

2

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Gebhart G, et al. Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598545 Free article. Clinical Trial.

3

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA. Mortimer JE, et al. J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630. Epub 2013 Dec 12. J Nucl Med. 2014. PMID: 24337604 Free PMC article.

4

The prognostic value of volume-based parameters using ¹⁸F-FDG PET/CT in gastric cancer according to HER2 status.

Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. Park JS, et al. Gastric Cancer. 2018 Mar;21(2):213-224. doi: 10.1007/s10120-017-0739-0. Epub 2017 Jun 22. Gastric Cancer. 2018. PMID: 28643145

5

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.

Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Janjigian YY, et al. J Nucl Med. 2013 Jun;54(6):936-43. doi: 10.2967/jnumed.112.110239. Epub 2013 Apr 11. J Nucl Med. 2013. PMID: 23578997 Free PMC article.

6

Construction of ¹²⁴I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients.

Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X, Shen L, Gao J, Yang Z, Zhu H. Guo X, et al. Gastric Cancer. 2020 Jul;23(4):614-626. doi: 10.1007/s10120-019-01035-6. Epub 2020 Jan 9. Gastric Cancer. 2020. PMID: 31919745

7

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. Ulaner GA, et al. Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820. Clin Nucl Med. 2017. PMID: 28872549 Free PMC article. Clinical Trial.

8

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with ⁸⁹Zr-trastuzumab PET imaging.

McKnight BN, Viola-Villegas NT. McKnight BN, et al. Breast Cancer Res. 2018 Oct 25;20(1):130. doi: 10.1186/s13058-018-1055-2. Breast Cancer Res. 2018. PMID: 30359299 Free PMC article.

9

⁸⁹Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.

Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. Bensch F, et al. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2300-2306. doi: 10.1007/s00259-018-4099-8. Epub 2018 Jul 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 30058029 Free PMC article.

10

Chemotherapy de-escalation using an ¹⁸F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A; PHERGain steering committee and trial investigators. Pérez-García JM, et al. Lancet Oncol. 2021 Jun;22(6):858-871. doi: 10.1016/S1470-2045(21)00122-4. Epub 2021 May 18. Lancet Oncol. 2021. PMID: 34019819 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year